Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]

References

  1. ^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
  2. ^ WHO: Consolidated List of Products
Allikas: https://en.wikipedia.org/wiki/Nebacumab
No tags for this post.